Q2 2026 saw 16% revenue growth (currency-adjusted), a 137% EBIT increase, and a 2.6pp gross margin improvement. Delays in U.S. prescription processes impacted timing but not demand, while Europe posted strong FX-adjusted growth. Dividend paid, net debt/EBITDA at 1.6x.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.